Abstract Background Personalized neoantigen vaccines offer a rational immunotherapeutic strategy for hepatocellular carcinoma (HCC), but their efficacy is limited by insufficient tumor immunogenicity and an immunosuppressive tumor microenvironment. Tumor-intrinsic factors that constrain vaccine-induced immune responses...
Xiao-Yuan Zheng, Jun Fu, Geng Chen et al.· Journal for ImmunoTherapy of...· 0 citations
This serum proteomic-based prognostic model accurately predicts surgical outcomes for BCLC stage B HCC patients and outperforms clinical stratification by identifying low-risk patients who may benefit from surgery and has the potential to improve survival and quality of life.
Mechanisms underlying the immunosuppressive microenvironment in hepatocellular carcinoma (HCC) extend beyond immune checkpoints to include metabolic competition. Here, we identify a metabolic evasion pathway driven by SLC1A5 overexpression, which enables HCC cells to sequester glutamine from the tumor microenvironmen...
Jingjing Nian, Zi-Ran Wang, Shi-Yi Chen et al.· Cell Death & Disease· 0 citations
This urine-based model enables dynamic assessment of tumor burden and early recurrence detection, surpassing conventional serum biomarkers and providing a clinically actionable tool for personalized surveillance and therapeutic decision-making in HCC.
Xiao-Hua Xing, En Hu, Lei Song et al.· Molecular & Cellular Proteom...· 0 citations
A biomimetic nanomedicine that integrates photothermal therapy (PTT), STING pathway activation, and immune checkpoint blockade to treat refractory HCC is developed and offers a promising therapeutic paradigm for photothermal immunotherapy of immune-cold HCC.